Drug Profile
Doxorubicin liposomal - Imunon
Alternative Names: Liposome encapsulated doxorubicin; LTLD; LTSDEL; Lyso-thermosensitive liposomal doxorubicin; ThermoDoxLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Celsion Corporation
- Developer Brigham and Womens Hospital; Harvard Medical School; Imunon; National Institute for Health Research; Oxford University Hospitals NHS Trust; University of Oxford; Utrecht University
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Liver cancer
- Phase II Breast cancer; Colorectal cancer; Liver metastases
- Phase I Pancreatic cancer
- Clinical Phase Unknown Bladder cancer
- No development reported Brain cancer; Glioblastoma
- Discontinued Prostate cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease) in Netherlands (IV, Liposomal)
- 01 Oct 2022 Children's National Research Institute terminates a phase I trial in Solid tumours (Second-line therapy or greater, In adults, In children, In adolescents) in USA (IV) due to low accrual (NCT02536183)
- 19 Sep 2022 Celsion Corporation is now called Imunon